Loading...
•
Sep 30, 2024
Vir Q3 2024 Earnings Report
Vir reported Q3 2024 financial results, highlighted the closing of an exclusive licensing agreement with Sanofi, and appointed Jason O’Byrne as CFO.
Key Takeaways
Vir Biotechnology reported a net loss of $213.7 million for the third quarter of 2024. The company closed an exclusive worldwide license agreement with Sanofi for three clinical-stage masked T-cell engagers and is focusing on infectious diseases and oncology. Jason O’Byrne was appointed as the new CFO.
Closed exclusive worldwide licensing agreement with Sanofi for three potential best-in-class clinical-stage dual-masked T-cell engagers.
Key Phase 2 SOLSTICE data in chronic hepatitis delta to be presented at AASLD 2024.
Jason O’Byrne appointed as Chief Financial Officer.
Preliminary data from the Phase 2 chronic hepatitis delta SOLSTICE study was presented at the European Study of the Liver (EASL) Meeting in June 2024.
Revenue by Segment
Forward Guidance
Vir Biotechnology updated its operating expense guidance for the full-year 2024, which includes the upfront in-process research and development expense associated with the clinical-stage T-cell engagers licensed through its agreement with Sanofi.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...